StocksMedium•4 November 2026•
1 min read
Insulet Stock Jumps 6.6% as Q3 Results Beat Estimates
Key Facts
1Insulet reported Q3 revenue of $842 million, representing a 19.2% year-over-year increase.
2Earnings per share beat estimates by $0.40, while the stock closed 6.6% higher in New York.
3The CEO expects slower growth in 2027 and anticipates rivals will reduce the Omnipod insulin pump's market share.
Insulet reported Q3 revenue of $842 million, representing a 19.2% year-over-year increase. AskTraders.com reported that earnings per share beat estimates by $0.40, leading the stock to close 6.6% higher in New York. The company's CEO expects slower growth in 2027 as rivals are anticipated to challenge the Omnipod insulin pump's market share.
PODD closed at $154.86 on November 3, 2026, having reached a session high of $156.98. These financial results arrived alongside a cautious outlook from management regarding increased competition in the medical device sector through 2027.